HKTB Extends Hong Kong Neighbourhoods to Launch West Kowloon for Promoting Art and Culture Tourism of the Neighbourhood
        <p class="bwalignc bwcellpmargin" style="text-align: center;">Oral Presentations:</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Abstract Name</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Authors</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Presentation ID</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Presentation Details</p>


        <p class="bwcellpmargin">Effects of evobrutinib, a Bruton’s tyrosine kinase inhibitor, on slowly expanding lesions: an emerging imaging marker of chronic tissue loss in multiple sclerosis</p>


        <p class="bwcellpmargin">D.L. Arnold, C. Elliott, X. Montalban, E. Martin, Y. Hyvert, D. Tomic</p>


        <p class="bwcellpmargin bwalignc" style="text-align: center;">115</p>


        <p class="bwcellpmargin">Session: Free Communications 2 - Treatment trials - ImmunomodulationDate: 14 October 2021Time: 16:57-17:04 CESTPresenter: Douglas L. Arnold</p>


        <p class="bwcellpmargin">Evobrutinib significantly reduces relapses and magnetic resonance imaging outcomes in patients with multiple sclerosis: association with baseline neurofilament light chain levels</p>


        <p class="bwcellpmargin">J. Kuhle, L. Kappos, X. Montalban, Y. Li, K. Thangavelu, Y. Hyvert, D. Tomic</p>


        <p class="bwcellpmargin bwalignc" style="text-align: center;">116</p>


        <p class="bwcellpmargin">Session: Free Communications 2 - Treatment trials - ImmunomodulationDate: 14 October 2021Time: 17:04-17:11 CESTPresenter: Jens Kuhle</p>


        <p class="bwcellpmargin">Single cell analysis of cerebrospinal fluid leukocytes in treated multiple sclerosis patients</p>


        <p class="bwcellpmargin">M. Heming, I. Lu, N. Schwab, D. Schafflick, C.C. Gross, H. Wiendl, G.M. zu Horste</p>


        <p class="bwcellpmargin bwalignc" style="text-align: center;">134</p>


        <p class="bwcellpmargin">Session: Free Communication 3: PathologyDate: 15 October 2021Time: 12:33-12:40 CESTPresenter: Gerd Meyer zu Hörste</p>


        <p class="bwcellpmargin">Activated Tfh1 cells infiltrate the cerebrospinal fluid in early multiple sclerosis</p>


        <p class="bwcellpmargin">J.Morille, M. Mandon, S.Rodriguez, A.Garcia, S.Wiertlewski, L.Berthelot, K.Tarte, C.Delaloy, P.Amé, D-A.Laplaud, L.Michel</p>


        <p class="bwcellpmargin bwalignc" style="text-align: center;">025</p>


        <p class="bwcellpmargin">Session: Scientific Session 2: Blood-Brain BarrierDate: 15 October 2021Time: 14:04-14:11 CESTPresenter: Marion Mandon</p>


        <p class="bwcellpmargin bwalignc" style="text-align: center;">MAVENCLAD® (cladribine tablets) ePoster Presentations:</p>


        <p class="bwcellpmargin">Long-term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-up in the CLASSIC-MS Study</p>


        <p class="bwcellpmargin">G. Giovannoni, T. Leist, A. Aydemir, E. Verdun Di Cantogno, on behalf of the CLASSIC-MS Steering Committee</p>


        <p class="bwalignc bwcellpmargin">P975</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Gavin Giovannoni</p>


        <p class="bwcellpmargin">Cladribine Tablets after treatment with natalizumab (CLADRINA) trial – Interim analyses</p>


        <p class="bwcellpmargin">P. Sguigna, A. Okai, J. Kaplan, K. Blackburn, L. Tardo, B. Hayward, U. Boschert, L. Lebson, N. Manouchehri, R. Hussain, O. Stuve</p>


        <p class="bwalignc bwcellpmargin">P987</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Peter Sguigna</p>


        <p class="bwcellpmargin">Improvements in QoL at 1 Year in Patients Treated With Cladribine Tablets for Highly Active Relapsing MS: An Interim Analysis of CLARIFY-MS</p>


        <p class="bwcellpmargin">A. Solari, X. Montalban, J. Lechner-Scott, F. Piehl, B. Brochet, D. Langdon, R. Hupperts, K. Selmaj, E.K. Havrdova, F. Patti, Brieva L, Maida EM, N. Alexandri, P. Kamudoni, A. Nolting, B. Keller</p>


        <p class="bwalignc bwcellpmargin">P238</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Alessandra Solari</p>


        <p class="bwcellpmargin">Post-Approval Safety of Cladribine Tablets With Particular Reference to COVID-19 Outcomes: An Update</p>


        <p class="bwcellpmargin">G. Giovannoni, J. Berger, T. Leist, D. Jack, A. Galazka, A. Nolting, D. Damian</p>


        <p class="bwalignc bwcellpmargin">P766</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Gavin Giovannoni</p>


        <p class="bwcellpmargin">High Adherence to Treatment With Cladribine Tablets for Multiple Sclerosis: Value-Added Benefit of a Nurse/Pharmacy-led Patient Support Programme During the COVID-19 Pandemic</p>


        <p class="bwcellpmargin">J. Oh, M.S. Freedman, K. Vernon, M. Ayer, C. Lemieux, K. Morgan, T. Quinn, T. Vella, A. Allignol, M. Stein, E. Verdun di Cantogno, M. Sabidó</p>


        <p class="bwalignc bwcellpmargin">P741</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Jiwon Oh</p>


        <p class="bwcellpmargin">Incidence of Infections and Severe Lymphopenia in Patients Newly Initiating Cladribine Tablets or Fingolimod for Treatment of Multiple Sclerosis: CLARION Study</p>


        <p class="bwcellpmargin">J. Hillert, H. Butzkueven, M. Soilu-Hänninen, T. Ziemssen, J. Kuhle, J.R. Berger, A. Aydemir, J. Sõnajalg, I. Bezemer, M. Sabidó</p>


        <p class="bwalignc bwcellpmargin">P767</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Jan Hillert</p>


        <p class="bwcellpmargin">Disease-Modifying Treatment Patterns of Patients With Multiple Sclerosis and Newly Treated With Cladribine Tablets or Fingolimod: An Interim Analysis of the CLARION Study</p>


        <p class="bwcellpmargin">H. Butzkueven, J. Hillert, J. Sõnajalg, M. Soilu-Hänninen, A. Aydemir, T. Ziemssen, J. Kuhle, M. Magyari, S. Wergeland, I. Bezemer, M. Sabidó</p>


        <p class="bwalignc bwcellpmargin">P742</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Helmut Butzkueven</p>


        <p class="bwcellpmargin">Risk of Cancer with Disease-Modifying Drugs in Multiple Sclerosis: A New-User Cohort Design in the French Nationwide Claims Database</p>


        <p class="bwcellpmargin">P. Bosco-Lévy, M. Sabidó, E. Guiard, P. Diez, C. Foch, C. Favary, J. Jové, E. Boutmy, P. Blin</p>


        <p class="bwalignc bwcellpmargin">P756</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Meritxell Sabidó</p>


        <p class="bwcellpmargin">A Multi-Country Cohort Database Study to Assess Pregnancy and Infant Outcomes in Women Exposed to Cladribine Tablets: CLEAR Study</p>


        <p class="bwcellpmargin">K. Hellwig, M. Magyari, T. McDonald, K. Gembert, S. Wergeland, M.k. Leinonen, A. Aydemir, M. Sabidó, A. Kawai, A. Arana</p>
         

        <p class="bwcellpmargin"> </p>


        <p class="bwalignc bwcellpmargin">P185</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Kerstin Hellwig</p>


        <p class="bwcellpmargin">MASTER-2 trial: Cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results)</p>


        <p class="bwcellpmargin">E.J. Fox, A.D. Bass, J. Aldridge, L.A. Lebson, D. Robertson</p>


        <p class="bwalignc bwcellpmargin">P851</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Edward Fox</p>


        <p class="bwcellpmargin">Evaluation of therapy satisfaction with cladribine tablets in RMS patients – Final results of the non-interventional study CLEVER</p>


        <p class="bwcellpmargin">C. Grothe, L. Cepek, G. Reifschneider, T. Ziemssen, J. Richter, T. Wagner</p>


        <p class="bwalignc bwcellpmargin">P859</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Joachim Richter</p>


        <p class="bwcellpmargin">Finnish cladribine tablets registry study 2 year data</p>


        <p class="bwcellpmargin">S. Atula, E. Jarvinen, H. Kuusisto, I. Rauma, M. Ryytty, J. Sipilä,</p>
         

        <p class="bwcellpmargin">M. Soilu-Hänninen, M. Viitala</p>


        <p class="bwalignc bwcellpmargin">P691</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Ilkka Rauma</p>

     
        <p class="bwcellpmargin">Outcomes after late Cladribine re-dosing in the Australian MSBase cohort</p>


        <p class="bwcellpmargin">H. Butzkueven, T. Spelman, S. Hodgkinson, A. Van der Walt, K. Buzzard, O. Skibina, T. Kalincik, J. Lechner-Scott, R. Macdonell, E. Verdun di Cantogno</p>


        <p class="bwalignc bwcellpmargin">P865</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Helmut Butzkueven</p>

     
        <p class="bwcellpmargin">Real-world experience with cladribine in the MSBase Registry</p>


        <p class="bwcellpmargin">H. Butzkueven, T. Spelman, MSBase Investigators (TBC), E. Verdun di Cantogno</p>


        <p class="bwalignc bwcellpmargin">P825</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Helmut Butzkueven</p>


        <p class="bwcellpmargin">Molecular biomarker signature associated with cladribine treatment</p>


        <p class="bwcellpmargin">N. Fissolo, L. Calvo-Barreiro, H. Eixarch, U. Boschert, C. Espejo, X. Montalban, M. Comabella</p>


        <p class="bwalignc bwcellpmargin">P584</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Nicolás Fissolo</p>


        <p class="bwcellpmargin">Effect of cladribine on differentiation of human neural precursor cells</p>


        <p class="bwcellpmargin">H. Eixarch, L. Calvo-Barreiro, N. Fissolo, U. Boschert, M. Comabella, X. Montalban, C. Espejo</p>


        <p class="bwalignc bwcellpmargin">P899</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Herena Eixarch</p>


        <p class="bwcellpmargin">Economic Analysis for Introduction of Cladribine Tablets as a Treatment for Relapsing-Remitting and High Disease Activity Multiple Sclerosis in Kuwait</p>


        <p class="bwcellpmargin">R. Alroughani, M.A. Al-Melh, S. Farouk, A. Abokoura, E. Alsultan, A Boshra, R. Alcharif, R. Ojeil, S. Basu, A. Verma</p>


        <p class="bwalignc bwcellpmargin">P280</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Raed Alroughani</p>


        <p class="bwcellpmargin">Effect of cladribine on COVID-19 serology responses following 2 doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis</p>


        <p class="bwcellpmargin">A. Vaknin-Dembinsky</p>


        <p class="bwalignc bwcellpmargin">P780</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Ariel Rechtman</p>


        <p class="bwcellpmargin">Effect of cladribine tablets in highly active MS monitored by global and regional brain atrophy status</p>


        <p class="bwcellpmargin">A. Raji, G. Winkler</p>


        <p class="bwalignc bwcellpmargin">P709</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Alaleh Raji</p>


        <p class="bwcellpmargin">Clinical Effectiveness and Safety of Cladribine Tablets for Patients Treated at least 12 Months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 10" (IMSE-10)</p>


        <p class="bwcellpmargin">V. Rosengren, E. Ekström, L. Forsberg, S. Kågström, J. Hillert, P. Nilsson, C. Dahle, A. Svenningsson, J. Lycke, A-M. Landtblom, J. Burman, C. Martin, P. Sundström, M. Gunnarsson, F. Piehl, T. Olsson</p>


        <p class="bwalignc bwcellpmargin">P743</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Victoria Rosengren</p>


        <p class="bwcellpmargin">Real-world patient profile of cladribine tablets in multiple sclerosis patients from Argentina</p>


        <p class="bwcellpmargin">Rojas JI, Alonso R, Luetic G, Pappolla A, Miguez J, Patrucco L, Cohen L, Garcea O, Casas M, Silva B, Deri N, Liwacki S, Silva E, Piedrabuena R et al.</p>


        <p class="bwalignc bwcellpmargin">P853</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Juan Ignacio Rojas</p>


        <p class="bwcellpmargin">Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy</p>


        <p class="bwcellpmargin">N. Vickaryous, A.N. Asardag, J. Bestwick, S.N. Shah, K. George, K. Schmierer, G. Giovannoni, D. Baker, A. Kang, R. Dobson</p>


        <p class="bwalignc bwcellpmargin">P950</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Nikki Vickaryous</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Rebif® (interferon beta-1a) subcutaneous injection ePoster Presentations:</p>


        <p class="bwcellpmargin">Development and Interrelation of Whole-Brain Atrophy and Lesion Volume During 5 Years’ Treatment With Subcutaneous Interferon Beta-1a in Patients With a First Clinical Demyelinating Event in the REFLEX/ION Study</p>


        <p class="bwcellpmargin">R.M. Mattiesing, G. Gentile, I. Brouwer, D. Jack, A. Seitzinger, F. Barkhof, N. De Stefano, B.M.J. Uitdehaag, J.W.R. Twisk, M. Battaglini, H. Vrenken</p>


        <p class="bwalignc bwcellpmargin">P430</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Rozemarijn Mattiesing</p>


        <p class="bwcellpmargin">Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions During 5 Years’ Treatment With Subcutaneous Interferon Beta-1a in Patients With a First Clinical Demyelinating Event in the REFLEX/ION Study</p>


        <p class="bwcellpmargin">G. Gentile, R.M. Mattiesing, I. Brouwer, D. Jack, A. Seitzinger, F. Barkhof, N. De Stefano, B.M.J. Uitdehaag, H. Vrenken, M. Battaglini</p>


        <p class="bwalignc bwcellpmargin">P458</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Giordano Gentile</p>


        <p class="bwcellpmargin">Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon Beta-1a in the REFLEX Trial</p>


        <p class="bwcellpmargin">M. Coray, A. Seitzinger, S. Roy, M.S. Freedman, F. Barkhof, G. Comi, N. De Stefano, L. Kappos, J. Kuhle, M. Mehling</p>


        <p class="bwalignc bwcellpmargin">P674</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Mali Coray</p>


        <p class="bwcellpmargin">INFORM – Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy – a Register-Based Drug Utilisation Study in Finland and Sweden</p>


        <p class="bwcellpmargin">M. Sabidó, K. Suzart-Woischnik, N. Grimes, L.M. Prach, L. Zhao, K.M. Hakkarainen</p>


        <p class="bwalignc bwcellpmargin">P794</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Meritxell Sabido</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Evobrutinib ePoster Presentations:</p>


        <p class="bwcellpmargin">Safety profile characterization of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus</p>


        <p class="bwcellpmargin">X. Montalban, D. Wallace, M.C. Genovese, D. Tomic, D. Parsons-Rich, C. Le Bolay, A. Kao, H. Guehring</p>


        <p class="bwalignc bwcellpmargin">P727</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Xavier Montalban</p>


        <p class="bwcellpmargin">The role of human and mouse BTK in myeloid cells</p>


        <p class="bwcellpmargin">C. Bassani, M. Molinari, V. Martinelli, R. Grenningloh, U. Boschert, G. Comi, G. Martino, L. Muzio, C. Farina</p>


        <p class="bwalignc bwcellpmargin">P656</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Cinthia Farina</p>


        <p class="bwcellpmargin">Targeting BTK in chronic CNS autoimmunity inhibits activation of microglia</p>


        <p class="bwcellpmargin">A. Geldaris, S. Torke, R. Grenningloh, U. Boschert, W. Brück, M.S. Weber</p>


        <p class="bwalignc bwcellpmargin">P971</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Anastasia Geladaris</p>


        <p class="bwalignc bwcellpmargin" style="text-align: center;">Non-Product Specific ePoster Presentations:</p>


        <p class="bwcellpmargin">DISCOntinuation of disease-modifying therapies in MS (DISCOMS) Extension – Study Design and Baseline Demographics</p>


        <p class="bwcellpmargin">E. Engebretson, G. Cutter, R. Fox, I. Kister, A. Miller, C. Morgan, R. Seale, J.R. Corboy</p>


        <p class="bwalignc bwcellpmargin">P751</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: John Corboy</p>


        <p class="bwcellpmargin">Genome-wide mapping of patient’s autoantibody targets to understand and predict Multiple Sclerosis pathogenesis and patient responses to Interferon β-1a therapy</p>


        <p class="bwcellpmargin">E.B. DiCillo, E. Kountikov, M. Zhu, W. Zhang, B. Hayward, D.E. Harlow, S. Lanker, J.L. Bennet, T.F. Tedder</p>


        <p class="bwalignc bwcellpmargin">P361</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Europe B DiCillo</p>


        <p class="bwcellpmargin">Towards a new resource for the MS brain: a cross-brain bank proteomic atlas of non-lesional neocortex</p>


        <p class="bwcellpmargin">P. Bouman, D. Pitt, D. Reich, J. Schneider, D. Bennett, R. Nagra, R. Reynolds, J. Geurts, J. Corboy, P. De Jager</p>


        <p class="bwalignc bwcellpmargin">P317</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Philip De Jager</p>


        <p class="bwcellpmargin">Multiplexed imaging of the multiple sclerosis meninges using mass cytometry</p>


        <p class="bwcellpmargin">V. Ramaglia, M. Zuo, N. Fransen, S. Zandee, A. Prat, I. Huitinga, A. Bar-Or, J.L. Gommerman</p>


        <p class="bwalignc bwcellpmargin">P319</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Valeria Ramaglia</p>


        <p class="bwcellpmargin">Interprofessional collaboration and patient-provider communication challenges in MS care: A mixed-methods needs assessment</p>


        <p class="bwcellpmargin">S. Péloquin, K. Schmierer, J. Oh, T. Leist, S. Murray, P. Lazur</p>


        <p class="bwalignc bwcellpmargin">P903</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Sophie Peloquin</p>


        <p class="bwcellpmargin">Neuropsychological measures associated with disease severity in pediatric onset multiple sclerosis</p>


        <p class="bwcellpmargin">N. Gur, E. Ganelin Cohen, T. Pilowsky Peleg</p>


        <p class="bwalignc bwcellpmargin">P990</p>


        <p class="bwcellpmargin">Date: 13 October 2021Time: 16:45-18:45 CESTPresenter: Noa Gur</p>
Disclaimer:
This Press Release has not been vetted or endorsed by The Eastern Herald’s editorial staff.
Follow us on:
Business Wire India
The Business Wire India news distribution platform ensures that your news is disseminated instantaneously through key information systems.

Public Reaction